3DVH

K131862 · Sun Nuclear Corporation · IYE · Aug 21, 2013 · Radiology

Device Facts

Record IDK131862
Device Name3DVH
ApplicantSun Nuclear Corporation
Product CodeIYE · Radiology
Decision DateAug 21, 2013
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 892.5050
Device ClassClass 2
AttributesSoftware as a Medical Device

Intended Use

Model 1212 3DVH is a radiotherapy dose delivery quality assurance (QA) software application intended to estimate the dosimetric impacts of the deviations and imperfections of a treatment delivery device, and its accessories, on the 3D patient dose volume as defined by a treatment planning system (TPS). These dosimetric impacts are based upon QA measurement of the radiation dose distributions that are delivered to a phantom.

Device Story

Software application (Model 1212 3DVH) for radiotherapy quality assurance; inputs include measured radiation dose distributions from phantom delivery and planned patient dose volume from treatment planning system (TPS). Patented dose algorithm (US patent #7,945,022) applies perturbations to TPS dose volume based on measured data to estimate actual patient dose volume. Used offline by clinicians to compare estimated dose to planned dose; informs clinical decision-making regarding treatment delivery capability. Benefits include improved verification of treatment delivery accuracy before patient treatment commences.

Clinical Evidence

Bench testing and clinical settings. Performance testing included benchmarking of dose calculation algorithm components and integrated system. Validation included confirmation of computed dose volume histogram data and comparison tools (dose difference, distance-to-agreement, gamma index analysis). No specific clinical trial metrics (e.g., sensitivity/specificity) reported; device shown to perform within design specifications and industry guidelines.

Technological Characteristics

Software-based QA application. Inputs: DICOM data from third-party treatment systems. Features: DVH display, color-wash dose display, structure-based dose statistics. Algorithm: Patented dose perturbation method (US patent #7,945,022). Connectivity: Integrates with third-party TPS.

Indications for Use

Indicated for radiotherapy dose delivery quality assurance (QA) to estimate dosimetric impacts of treatment delivery device deviations on 3D patient dose volumes. Used by clinicians to assess if treatment delivery devices and accessories can deliver treatment as prescribed.

Regulatory Classification

Identification

A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K13/862 Image /page/0/Picture/1 description: The image shows the logo for Sun Nuclear Corporation. The logo consists of a stylized image of a circle with horizontal lines inside it, followed by the words "SUN NUCLEAR" in large, bold letters. Below that, the word "corporation" is written in smaller letters. Your Most Valuable QA & Dosimetry Tools # Section 6 - 510(k) Summary Provided in accordance with 21 CFR 807.92 (c) #### 1 General Provisions Date Prepared: June 21, 2013 Submitted by: Sun Nuclear Corporation 3275 Suntree Blvd. Melbourne, FL 32940 Ph: 321-259-6862 Fax: 321-259-7979 Web: www.sunnuclear.com AUG 2 1 2013 Contact Person: Jeff Kapatoes jeffkapatoes@sunnuclear.com Classification Name: Accelerator, Linear, Medical - Common Name: Dosimetric Quality Assurance for Patient Specific Radiation Treatment - Proprietary Names: Model 1212 3DVH Establishment Registration Number: 1038814 Classification: Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Product code: IYE Predicate Device: | Model Name: | Compass | |---------------|------------------------------| | Common Name: | Accelerator, linear, medical | | 510(k) # | K072374 | | Manufacturer: | Scanditronix Wellhdfer GmbH | | Cleared: | Dec 7, 2007 | {1}------------------------------------------------ Image /page/1/Picture/1 description: The image shows the logo for Sun Nuclear Corporation. The logo consists of a stylized sun symbol on the left, followed by the words "SUN NUCLEAR" in bold, sans-serif font on the top line. Below that, the word "corporation" is written in a smaller, sans-serif font. The entire logo is in black and white. #### 2 Description: The Sun Nuclear 3DVH product, model 1212, is a software application that creates an estimated patient dose distribution using data measured during delivery of the treatment plan to certain 2D or 3D detector arrays and the planning patient dose volume computed by the treatment planning system (TPS) as inputs. The patented 3DVH dose algorithm (US patent #7,945,022) uses the measured data to make perturbations to the TPS patient dose volume to produce the estimated patient dose volume. From a comparison of the 3DVH result to the TPS planned dose, a qualified clinician makes the decision whether the TDD along with its accessories (including the treatment planning system, or TPS) is capable of delivering the treatment as prescribed. #### ന Intended Use Statement: Sun Nuclear Corporation (SNC) Model 1212 3DVH has the following intended use: Model 1212 3DVH is a radiotherapy dose delivery quality assurance (QA) software application intended to estimate the dosimetric impacts of the deviations and imperfections of a treatment delivery device, and its accessories, on the 3D patient dose volume as defined by a treatment planning system (TPS). These dosimetric impacts are based upon QA measurement of the radiation dose distributions that are delivered to a phantom. While the exact wording of this Intended Use and that for the predicate are not identical, the intended uses are substantively the same with one exception: Compass claims input from "online or offline measurements". "Online" use implies with the patient present during patient treatment. Model 3DVH is only intended with input from "offline" measurements, i.e without the patient present. This difference is not critical to the intended diagnostic use of the device since 3DVH is intended for quality assurance performed without the patient present, typically done before treatment commences. The difference does not affect the safety and effectiveness of the device when used as labeled because 3DVH is only intended to be used with input acquired offline. Use of online measurements would constitute a different intended use and thus a different product. #### ব Technological Characteristics Model 1212 3DVH shares both similar and different technological characteristics. Similar characteristics include the use DICOM input data from third party treatments systems and analysis tools such as dose volume histogram (DVH) display, color-wash dose display for multiple anatomical planes, and structure-based dose statistics. A different technological characteristic is the algorithm used to produce the estimated patient dose volume. #### 5 Performance Data 3DVH has been tested in non-clinical and clinical settings, and it has been shown that this device performs within its design specifications and industry-specific quidelines. Performance testing included extensive benchmarking of the dose calculation algorithm (its individual components and as an integrated whole). Performance testing also included confirmation of the computed dose volume histogram data and comparison tools such as dose different, distance-to-agreement, and gamma index analysis. Based on the results of this performance testing, Model 1212 3DVH is as safe, as effective, and performs as well or better than the predicate device. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles an abstract human figure or a caduceus, which is a symbol often associated with healthcare. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 August 21. 2013 Sun Nuclear Corporation % Jeff Kapatoes. Ph.D. Product Manager 3275 Suntree Blvd. MELBOURNE FL 32940 Re: K131862 Trade/Device Name: Model 1212 3DVH Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: June 21, 2013 Received: June 27, 2013 Dear Dr. Kapatoes: We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Isting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you. however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801): medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/McdicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours. Jamingh. Mense Janine M. Morris Director, Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ### Indications for Use Form # 510(k) Number (if known): K131862 ## Device Name: Model 1212 3DVH Indications for Use: ### Intended Use: Model 1212 3DVH is a radiotherapy dose delivery quality assurance (QA) software application intended to estimate the dosimetric impacts of the deviations and imperfections of a treatment delivery device. and its accessories, on the 3D patient dose volume as defined by a treatment planning system (TPS). These dosimetric impacts are based upon QA measurement of the radiation dose distributions that are delivered to a phantom. Perseription Use X (Part 21 CFR 801 Subpart D) OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH. Office of In Vitro Diagnostics and Radiological Health (OJR) Jaming M. Mense Division Sign-Off Office of In Vitro Diagnostics and Radiological Health 510(k) Page 1 of 1
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...